

# Antimicrobial Susceptibility Profiles and Strain Type Diversity of *Campylobacter jejuni* Isolates from Turkeys in Eastern North Carolina<sup>∇†</sup>

Weimin Gu, Robin M. Siletzky, Sandra Wright, Mohammed Islam, and Sophia Kathariou\*

Department of Food Science, North Carolina State University, Raleigh, North Carolina 27695

Received 29 August 2008/Accepted 12 November 2008

***Campylobacter jejuni* is one of the most common bacterial causes of human gastroenteritis, and recent findings suggest that turkeys are an important reservoir for this organism. In this study, 80 *C. jejuni* isolates from eastern North Carolina were characterized for resistance to nine antimicrobials, and strain types were determined by *fla* typing, pulsed-field gel electrophoresis (PFGE) with *Sma*I and *Kpn*I, and (for 41 isolates) multilocus sequence typing (MLST). PFGE analysis suggested that many of the isolates (37/40 [ca. 93%]) in a major genomic cluster had DNA that was partially methylated at *Sma*I sites. Furthermore, 12/40 (30%) of the isolates in this cluster were completely resistant to digestion by *Kpn*I, suggesting methylation at *Kpn*I sites. MLST of 41 isolates identified 10 sequence types (STs), of which 4 were new. Three STs (ST-1839, ST-2132 and the new ST-2934) were predominant and were detected among isolates from different farms. The majority of the isolates (74%) were resistant to three or more antimicrobials, and resistance to ciprofloxacin was common (64%), whereas resistance to the other drug of choice for treatment of human campylobacteriosis, erythromycin, was never encountered. Most (33/34) of the kanamycin-resistant isolates were also resistant to tetracycline; however, only ca. 50% of the tetracycline-resistant isolates were also kanamycin resistant. Isolates with certain antimicrobial resistance profiles had identical or closely related strain types. Overall, the findings suggest dissemination of certain clonal groups of *C. jejuni* isolates in the turkey production industry of this region.**

*Campylobacter* is a leading bacterial agent of food poisoning in the United States and other industrialized nations. The majority (>90%) of campylobacteriosis cases are caused by *Campylobacter jejuni*, with the remainder being caused primarily by *Campylobacter coli* (12, 14). In addition to acute gastrointestinal symptoms, substantial disease burden due to *C. jejuni* infection is associated with severe sequelae, including the autoimmune-mediated demyelinating neuropathies Guillain-Barré and Miller Fisher syndromes (28, 32). Human campylobacteriosis is typically self-limited; when antibiotic treatment is suggested, the drugs of choice are ciprofloxacin (or other fluoroquinolones) and erythromycin (or other macrolides) (29, 32).

Transmission to humans mainly involves contaminated food, untreated drinking water, or raw milk (1, 12). Raw or undercooked poultry is a major risk factor for food-borne campylobacteriosis, either directly or through cross-contamination of foods that are ready to eat (3). In the United States and many other nations, significant effort has been invested in determinations of *Campylobacter* prevalence in broiler carcasses and in assessment of the associated public health risks (for examples, see references 7, 10, and 34).

In comparison with studies involving broilers, relatively few reports are available on *C. jejuni* isolates from turkeys. Studies

in Europe indicated that *C. jejuni* was frequently isolated from turkeys preharvest or from turkey meat (4, 36, 37). Surveys in the United States have revealed that both *C. jejuni* and *C. coli* colonize turkeys, with the relative prevalence of the two species varying among different flocks (33, 39, 40) and among samples from different processing plants (23). In certain flocks, treatments such as feed withdrawal and transport also appeared to influence the *C. jejuni*-to-*C. coli* ratio (39). Production systems (organic versus conventional) may also impact this ratio, with the *C. jejuni*-to-*C. coli* ratio being higher in samples from conventionally grown turkeys than in those from birds grown organically (24). Previous surveys of five commercial turkey flocks in eastern North Carolina (2001 to 2003) revealed a high prevalence of *Campylobacter* isolates, primarily *C. coli*, in turkeys, and a high prevalence of resistance to several antimicrobials (22, 33). Resistance to several antimicrobials was also prevalent among *C. coli* and *C. jejuni* isolates from conventionally grown turkeys (24). However, strain subtyping information on *C. jejuni* isolates from turkeys in the United States is limited. Furthermore, possible correlations between strain types and antimicrobial susceptibility profiles of the organisms remain unidentified.

Eastern North Carolina is a major contributor to turkey production in the United States. Recently, we described the relative prevalence of *Campylobacter* isolates, and of *C. jejuni* versus *C. coli*, in fecal samples from turkeys grown on farms located in close proximity to swine farms in this region. *C. jejuni* was found to be the predominant species (isolated from 60% of the *Campylobacter*-positive samples), and its prevalence in samples from different flocks varied from 31% to 86% (40). In this study, 80 *C. jejuni* isolates from this region were characterized for susceptibility to nine antimicrobials. In addi-

\* Corresponding author. Mailing address: North Carolina State University, Department of Food Science, CB 7624, Raleigh, NC 27695-7624. Phone: (919) 513-2075. Fax: (919) 513-0014. E-mail: sophia\_kathariou@ncsu.edu.

† Supplemental material for this article may be found at <http://aem.asm.org/>.

∇ Published ahead of print on 21 November 2008.

tion, the isolates were subtyped using three different strain subtyping tools: *fla* typing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST). These investigations were pursued to characterize the population structure of *C. jejuni* isolates from turkeys grown in this region and to elucidate the possible associations between strain types and antimicrobial susceptibility phenotypes of the organisms.

#### MATERIALS AND METHODS

**Campylobacter strains and growth conditions.** The *C. jejuni* isolates in this study are listed in Table 1. These isolates were from the *Campylobacter* culture collection in our laboratory and had been isolated between 2003 and 2006 from fecal or cecal samples from turkeys grown conventionally in eastern North Carolina. Information on specific antimicrobials that may have been administered to the flocks therapeutically, or for growth promotion, was not available. The majority of these isolates ( $n = 63$ ) were chosen from a larger collection of *C. jejuni* isolates obtained during a survey of *Campylobacter* colonization of turkeys in North Carolina, from 2003 to 2005 (40). The remaining 17 isolates were obtained during 2006. To maximize diversity, isolates were chosen so as to represent different flocks, farms, and antibiotic susceptibility phenotypes (based on original screens at a single concentration for each respective antimicrobial).

Bacteria were grown as described previously (33) on tryptic soy agar with 5% sheep blood (Remel, Lenexa, KS) at 42°C for 48 h under microaerobic conditions and preserved at -80°C in cryovials containing brain heart infusion medium (Difco, Sparks, MD) with 20% glycerol.

**Antibiotic susceptibility and MIC determinations.** MICs were determined for the following nine antimicrobial agents: ampicillin, chloramphenicol, ciprofloxacin, erythromycin, gentamicin, kanamycin, nalidixic acid, streptomycin, and tetracycline. Antimicrobials were purchased from Sigma Chemical Co. (St. Louis, MO), except for gentamicin, kanamycin, nalidixic acid, and ciprofloxacin, which were purchased from Fisher Biotech (Fair Lawn, NJ). The dilution range used for all tested antimicrobial agents was from 0.5 to 256 µg/ml (Table 2). MICs were determined using the agar dilution method as described previously (24). *C. jejuni* ATCC 33560 (purchased from the American Type Culture Collection) was used as the quality control strain. The plates were incubated at 42°C for 48 h under microaerobic conditions, and the MIC was defined as the lowest concentration of an antimicrobial agent that inhibited growth on the plates. The quality control strain and all tested isolates were also grown on Mueller-Hinton agar plates (Becton Dickinson, Sparks, MD) without antimicrobials to ensure viability. The MIC results of *C. jejuni* ATCC 33560 were within a 3-dilution range for ampicillin, kanamycin, nalidixic acid, and chloramphenicol, for which quality control ranges are not currently available. The resistance breakpoints for all antimicrobials (except for chloramphenicol and streptomycin) were those described previously (24). For chloramphenicol, the resistance breakpoint was that used for *Enterobacteriaceae*, as recommended by the Clinical and Laboratory Standards Institute (8). The resistance breakpoint used for streptomycin was ≥64 µg/ml, as described previously (17) (Table 2).

**DNA extractions, species confirmation, *fla* typing, PFGE, and MLST.** Genomic DNA was extracted using the Qiagen DNeasy kit (Qiagen Inc., Valencia, CA) according to the manufacturer's protocol. To confirm that the isolates were *C. jejuni*, hip primers were used in PCR, as described previously (33). PFGE was done using SmaI and KpnI (New England Biolabs) following the PulseNet protocol (<http://www.cdc.gov/PULSENET/protocols.htm>), with a few minor modifications as described by D'lima et al. (9), and *fla* typing was performed as described previously (33). Tagged image file format images of banding patterns resulting from *fla* typing and PFGE were analyzed by BioNumerics (version 4.6; Applied Maths, Saint-Martens-Latem, Belgium). Band position tolerance using the Dice coefficient was set at 1%, and clustering was performed using the unweighted-pair group method with arithmetic averages, as described previously (9). For MLST, we employed previously described primer sets for seven house-keeping genes (*aspA*, *atpA*, *glxA*, *gluA*, *glyA*, *pgm*, and *tkr*), and PCR conditions were as described previously (27) with minor modifications (95°C for 45 s, 53°C for 45 s, and 72°C for 2 min, over 32 cycles). Amplicons were sequenced at the Genome Research Laboratory of North Carolina State University, and at Davis Sequencing (Davis, CA). Sequence type (ST) identifications were done using the *C. jejuni/C. coli* MLST database (<http://pubmlst.org/campylobacter>), and new sequences were assigned new allele numbers and STs as described previously (26). Putative phylogenetic relationships among the STs were presented using a minimum spanning tree constructed with BioNumerics (version 4.6), as de-

scribed previously (9). The numerical index of discrimination ( $D$ ) was determined as described previously (18).

#### RESULTS

**Antimicrobial susceptibility phenotypes and MICs.** MIC determinations revealed that all 80 *C. jejuni* isolates were susceptible to erythromycin, chloramphenicol, and gentamicin. There was always agreement between nalidixic acid and ciprofloxacin resistances, and since they have the same mechanism of action, the results for these two antimicrobials are reported here as a single class. No pansensitive isolates were identified. Only five isolates were resistant to a single antimicrobial; SC1453, 8665, and 8904 were resistant only to ampicillin, whereas 11618 and 11640MD were resistant only to tetracycline (Table 1). Resistance to four or five antimicrobials was encountered among 36 (45%) and 13 (16.3%) isolates, respectively (Tables 1 and 3). Thus, even though a total of 13 different antimicrobial resistance profiles were identified among the 80 *C. jejuni* isolates, multidrug resistance profiles (resistance to three or more antimicrobials, with nalidixic acid and ciprofloxacin counted as one) were found in the majority (ca. 74%) of the isolates (Tables 1 and 3).

When the prevalence of resistance to individual antimicrobials was assessed, we noted high prevalence (60% to ca. 98%) of resistance to ampicillin, tetracycline, streptomycin, and nalidixic acid/ciprofloxacin (Table 2). There was a wide range of MICs for all of the antimicrobials, especially tetracycline and streptomycin, for which the widest range (32 to >256 µg/ml) was observed (Table 2). MICs exceeding the maximum of the tested range (>256 µg/ml) were noted in the majority of the isolates resistant to ampicillin (76/78 [97.4%]), kanamycin (33/34 [97.1%]), or streptomycin (36/48 [75%]) (Table 2).

**Association between resistance to kanamycin and resistance to tetracycline.** A strong correlation was found between kanamycin resistance and resistance to tetracycline. Of the 34 kanamycin-resistant isolates, all but one (strain 9778) were also resistant to tetracycline. The reverse, however, was not true. Only ca. 50% of the tetracycline-resistant isolates were also kanamycin resistant (Tables 1 and 3).

**Strain subtyping reveals three predominant clusters.** All 80 isolates were subtyped by *fla* typing and PFGE using SmaI and KpnI (Fig. 1). In addition, a subset of 41 of the 80 isolates was chosen for analysis by MLST. These 41 isolates were chosen to represent different subtypes based on *fla* typing and PFGE profiles, as well as diverse antimicrobial susceptibility profiles. The resulting numerical indices of discrimination ( $D$ ) for *fla* typing, PFGE with SmaI, PFGE with KpnI, and MLST, each used separately, were 0.97, 0.969, 0.958, and 0.824, respectively. Higher  $D$  values were obtained when the subtyping schemes were combined;  $D$  for the combination of *fla* typing and PFGE (with both SmaI and KpnI) was 0.996 and was not appreciably changed ( $D = 0.995$ , for the subset of 41 isolates that was typed by MLST) when MLST subtyping data were also included.

PFGE analysis revealed that 14 isolates (18%) failed to cut with KpnI, in spite of repeated efforts, and therefore, band-based subtyping analysis of these isolates was based on *fla* typing and PFGE using SmaI (Fig. 1). Bionumerics-based cluster analysis of the compiled *fla* types and PFGE profiles iden-

TABLE 1. *C. jejuni* isolates characterized in this study

Isolate <sup>a</sup>	Date	Age (wk)	Company	Farm	Antimicrobial resistance <sup>b</sup>	Antimicrobial resistance profile	ST
<b>5966</b>	31 Oct 2003	5.5	D	2	AQ	2	2934
<b>5996</b>	14 Nov 2003	5.5	D	13	ATSQ	10	2936
<b>6009</b>	14 Nov 2003	7.5	D	2	ATSKQ	12	
<b>6013</b>	14 Nov 2003	7.5	D	2	ATKQ	8	
<b>6040</b>	1 Dec 2003	8	D	13	ATQ	6	
<b>6041</b>	1 Dec 2003	8	D	13	ATKQ	8	
<b>6102</b>	15 Dec 2003	10	D	13	ATSKQ	12	2132
<b>6137</b>	15 Feb 2004	5	D	1	ATSK	11	2132
<b>6161</b>	19 Feb 2004	7	D	1	ATSQ	10	
<b>6209</b>	11 Mar 2004	10	D	1	ATSKQ	12	1162
<b>6447</b>	8 Apr 2004	8	D	8	ATKQ	8	1796
<b>6451</b>	8 Apr 2004	8	D	8	ATSQ	10	
<b>6470</b>	9 Apr 2004	7	D	4	ATSK	11	
<b>6471</b>	9 Apr 2004	7	D	4	AT	5	
<b>6532</b>	22 Apr 2004	10	D	8	ATSQ	10	1839
<b>6535</b>	22 Apr 2004	10	D	8	AT	5	
<b>6565</b>	29 Apr 2004	10	D	5	ATS	9	1839
<b>6608</b>	4 May 2004	11	D	4	ATSQ	10	1839
<b>6628</b>	6 May 2004	12	D	8	ATSQ	10	1839
<b>6631</b>	6 May 2004	12	D	8	AT	5	1839
<b>7287</b>	13 July 2004	8	D	2	ATSQ	10	1839
<b>7290</b>	13 July 2004	8	D	2	ATS	9	
<b>7294</b>	13 July 2004	8	D	2	ATSK	11	
<b>7320</b>	13 July 2004	8	D	2	ATSQ	10	
<b>7812</b>	5 Aug 2004	10	D	5	ATK	7	
<b>7813</b>	5 Aug 2004	10	D	5	AS	3	2132
<b>7895</b>	11 Aug 2004	12	D	2	ATKQ	8	
<b>8092</b>	20 Aug 2004	12	D	5	ATSQ	10	
<b>8359</b>	22 Sep 2004	5	D	3	AT	5	
<b>8633</b>	6 Oct 2004	7	D	3	ATKQ	8	
<b>8635</b>	6 Oct 2004	7	D	3	AQ	2	2934
<b>8647</b>	6 Oct 2004	7	D	3	ATSKQ	12	
<b>8665</b>	6 Oct 2004	7	D	3	A	1	1838
<b>8803</b>	23 Oct 2004	7	D	12	ATSKQ	12	
<b>8828</b>	23 Oct 2004	7	D	12	ATKQ	8	
<b>8865</b>	27 Oct 2004	10	D	3	ATKQ	8	
<b>8878</b>	27 Oct 2004	10	D	3	ATK	7	
<b>8904</b>	27 Oct 2004	10	D	3	A	1	1838
<b>8950</b>	10 Nov 2004	10	D	12	ATQ	6	
<b>8953</b>	10 Nov 2004	10	D	12	ATSK	11	
<b>8954</b>	10 Nov 2004	10	D	12	ATSQ	10	
<b>8959</b>	10 Nov 2004	10	D	12	ATS	9	
<b>9044</b>	17 Nov 2004	13	D	3	ATSK	11	
<b>9355</b>	30 Dec 2004	6	D	12	AS	3	2132
<b>9585</b>	1 Feb 2005	7	D	3	AT	5	
<b>9669</b>	2 Feb 2005	11	D	12	ATSKQ	12	
<b>9778</b>	23 Feb 2005	14	D	12	ASKQ	4	
<b>9838</b>	24 Feb 2005	10	D	3	ATSQ	10	
<b>9850</b>	24 Feb 2005	10	D	3	AS	3	2132
<b>10287</b>	6 Jul 2005	7	D	1	ATSKQ	12	
<b>10296</b>	6 Jul 2005	7	D	1	AQ	2	
<b>10297</b>	6 Jul 2005	7	D	1	AQ	2	2934
<b>10306</b>	6 Jul 2005	7	D	1	AS	3	2132
<b>10328</b>	6 Jul 2005	7	D	1	ATSK	11	
<b>10371</b>	26 Jul 2005	10	D	1	ATSQ	10	2936
<b>10882</b>	9 Sep 2005	8	D	4	ATSKQ	12	1939
<b>10884</b>	9 Sep 2005	8	D	4	ATSQ	10	
<b>10888</b>	9 Sep 2005	8	D	4	ATS	9	
<b>10977</b>	23 Sep 2005	10	D	4	AQ	2	2934
<b>11055</b>	23 Sep 2005	10	D	8	ATSQ	10	
<b>11211</b>	17 Oct 2005	14	D	4	AS	3	2132
<b>11222</b>	17 Oct 2005	14	D	8	ATSKQ	12	
<b>11250</b>	17 Oct 2005	14	D	8	AQ	2	
11599	26 Sep 2006	12	A	6	ATSKQ	12	1839
11600	26 Sep 2006	12	A	6	ATSKQ	12	1839
11603	26 Sep 2006	11	A	17	ATQ	6	1839
11607	26 Sep 2006	13	A	7	ATSK	11	2132
11618	6 Oct 2006	8	D	10	T	13	1698
11619	6 Oct 2006	8	D	10	ATKQ	8	2934
11640	20 Oct 2006	10	D	11	ATKQ	8	2934
11599MD	26 Sep 2006	12	A	6	ATSK	11	2132
11600MD	26 Sep 2006	12	A	6	ATSKQ	12	2132
11601MD	26 Sep 2006	12	A	6	ATKQ	8	2934
11618MD	6 Oct 2006	8	D	10	ATSQ	10	2937
11640MD	20 Oct 2006	10	D	11	T	13	1698
SC1453	13 Dec 2006	3	A	9	A	1	2934
SC1471	13 Dec 2006	3.5	A	15	ATSKQ	12	1839
SC1486	13 Dec 2006	5	B	18	ATSQ	10	2935
SC1527	14 Dec 2006	2.5	C	14	ATQ	6	1839
SC1532	14 Dec 2006	7.5	C	16	ATSQ	10	2936

<sup>a</sup> Isolates in boldface type were a subset of the *C. jejuni* isolate collection obtained from a previously described survey (40).

<sup>b</sup> A, ampicillin; K, kanamycin; S, streptomycin; T, tetracycline; Q, (fluoro)quinolone (nalidixic acid and ciprofloxacin).

TABLE 2. MIC distributions and resistance rates of *C. jejuni* isolates from turkey farms

Antimicrobial	No. of isolates inhibited at indicated concn ( $\mu\text{g/ml}$ ) <sup>a</sup>											MIC <sub>50</sub> /MIC <sub>90</sub> ( $\mu\text{g/ml}$ )	No. (%) of resistant isolates
	0.5	1	2	4	8	16	32	64	128	256	>256		
Ampicillin	0	0	0	0	1	0	<b>0</b>	1	1	0	76	>256/>256	78 (97.5)
Chloramphenicol	2	5	32	36	5	0	<b>0</b>	0	0	0	0	4/4	0
Ciprofloxacin	27	1	1	<b>0</b>	1	8	29	11	2	0	0	32/64	51 (63.75)
Erythromycin	30	31	18	1	<b>0</b>	0	0	0	0	0	0	1/2	0
Gentamicin	32	45	2	1	0	<b>0</b>	0	0	0	0	0	1/1	0
Kanamycin	0	0	1	8	29	7	0	<b>1</b>	0	1	33	16/>256	34 (42.5)
Nalidixic acid	0	0	2	12	13	2	<b>0</b>	15	25	7	4	64/256	51 (63.75)
Streptomycin	1	8	11	2	0	2	1	<b>7</b>	9	3	36	128/>256	48 (60)
Tetracycline	2	3	8	1	1	<b>0</b>	2	5	28	21	9	128/>256	65 (81.25)

<sup>a</sup> Boldface numbers of isolates indicate that the corresponding MIC was the resistance breakpoint.

tified 69 distinct strain subtypes and yielded three major clusters of isolates (with overall identity within each cluster being >55%), designated A (22 isolates), B (40 isolates), and C (18 isolates). The isolates in the major clusters were derived from several different farms and time points during the 2003 to 2006 period (Fig. 1 and Table 1). Only a few were identical with both *fla* typing and PFGE. Eight pairs of isolates (three in cluster A and five in cluster B) exhibited identical *fla* and PFGE subtypes, with five of these eight subtypes involving organisms isolated at different times from the same farm (Fig. 1). The only subtype with more than two isolates consisted of four isolates (11600, 11603, 8092, and 9585) from four different farms and three different times (Fig. 1 and Table 1).

MLST analysis of 41 of the isolates identified 10 STs, of which four (2934 to 2937) were new. Three of the 10 STs were predominant, detected in 73% of the isolates, as follows: ST-2934 ( $n = 8$ ), ST-2132 ( $n = 10$ ), and ST-1839 ( $n = 12$ ). The apparent dissemination of these three STs was further evidenced by the fact that each was found in isolates from differ-

ent farms and from birds of different ages (Table 1). The remaining seven STs were represented by one to three isolates each (Fig. 2).

Construction of a minimum spanning tree to evaluate the relatedness among the 10 STs revealed two clusters, one including two predominant STs (ST-2132 and ST-2934) and the other including predominant ST-1839 and closely related ST-2935 and ST-2936 (Fig. 2). ST-2935 was the only ST in this cluster identified as belonging to a greater ST complex, specifically 1332. The second cluster was primarily comprised of STs belonging to ST complex 353 (STs 2934, 1162, 2132, 1838, and 2937) whereas distantly related ST-1796 was included in ST complex 257 (Fig. 2). An ST complex designation was not available for ST-1698 (<http://pubmlst.org/campylobacter>).

Isolates with the same STs were grouped into the same *fla* typing- and PFGE-based clusters (Fig. 1), with one exception; isolate 6102 (ST-2132) was placed in cluster B, whereas all other isolates with ST-2132 were in cluster C. Furthermore, isolates with closely related STs (e.g., 1839, 2935, and 2936) had related *fla* and PFGE fingerprints. Interestingly, even though STs 1162, 2132, and 2934 were closely related based on MLST (Fig. 2), they were placed into two different clusters based on *fla* typing and PFGE (Fig. 1).

Within each of the three predominant STs (ST-1839, ST-2132, ST-2934), several related strain subtypes could be identified with the combination of *fla* typing and PFGE (Fig. 3A to C). In several instances, isolates with the same ST and with identical PFGE patterns were differentiated by distinct *fla* types (e.g., 7287 and 10882 in Fig. 3A, 5966 and 8635 in Fig. 3C). Different antimicrobial profiles were noted for strains with the same ST, especially in the case of ST-1839 (five profiles) (Fig. 3A).

**PFGE data suggest DNA methylation among many isolates, mostly in cluster B.** In repeated trials, PFGE with SmaI suggested incomplete digestion of genomic DNA of 39 isolates, characterized by the appearance of multiple weak bands in the background between the major bands and a prominent high-molecular-weight band (ca. 1 Mb) at the top of each lane (Fig. 1). Furthermore, 14 isolates were completely resistant to digestion by KpnI and thus untypeable with this enzyme (Fig. 1). Digestion of these isolates with KpnI yielded only a large band of presumably undigested DNA, and the corresponding wells in the PFGE gels were unusually bright, also suggesting undigested DNA (see Fig. S1 in the supplemental material).

The majority (37/39 [ca. 95%]) of the isolates with DNA

TABLE 3. Strain subtypes of isolates with specific antimicrobial resistance profiles<sup>d</sup>

Antimicrobial resistance profile no.	Antimicrobial resistance pattern <sup>a</sup>	No. of isolates	ST(s) <sup>b</sup>	Subtype cluster (no. of isolates) <sup>c</sup>
1	A	3	1828 (2/3), 2934 (1/3)	A (3)
2	AQ	6	2934 (4/4)	A (6)
3	AS	5	2132 (5/5)	C (5)
4	ASKQ	1	ND	B (1)
5	AT	5	1839 (1/1)	A (1), B (4)
6	ATQ	4	1839 (2/2)	A (1), B (3)
7	ATK	2	ND	A (1), B (1)
8	ATKQ	10	2934 (3/4), 1796 (1/4)	A (9), B (1)
9	ATS	4	1839 (1/1)	B (4)
10	ATSQ	17	1839 (4/9), 2935 (1/9), 2936 (3/9), 2937 (1/9)	A (1), B (15), C (1)
11	ATSK	8	2132 (3/3)	B (2), C (6)
12	ATSKQ	13	1839 (4/7), 2132 (2/7), 1162 (1/7)	B (9), C (4)
13	T	2	1698 (2/2)	C (2)

<sup>a</sup> A, ampicillin; K, kanamycin; S, streptomycin; T, tetracycline; Q, (fluoro)quinolone (nalidixic acid and ciprofloxacin).


<sup>b</sup> Data in parentheses represent the number of isolates with the ST out of the total number of isolates. ND, not determined.

<sup>c</sup> Based on *fla* typing and PFGE profiles (Fig. 1).

<sup>d</sup> For the 13 antimicrobial resistance profiles, there were totals of 13 patterns, 80 isolates, 10 STs, 22 subtype cluster A isolates, 40 subtype cluster B isolates, and 18 subtype cluster C isolates.



Ita-PfGEona+PFGE-Kpn I  
Fla + Sma I + Kpn






FIG. 2. Minimum spanning tree depicting the clustering of 10 STs identified among 41 *C. jejuni* isolates. The tree was created using BioNumerics (version 4.6; Applied Maths). Each ST is represented by a circle, and the size of each circle is proportional to the number of isolates that comprise that ST. Thick, short lines indicate a single allele difference; thin, longer lines indicate two allele differences; and dashed lines represent three (black) or more (gray) allele differences. New STs are in boldface type. The shaded area depicts clusters of highly related STs. ST complex designations were obtained from <http://pubmlst.org/campylobacter>. ST complex designations were not available for STs 1698, 2936, and 1839.

partially digested with *Sma*I were in cluster B, and conversely, most (37/40 [ca. 93%]) of the cluster B isolates had such partially digested DNA. When known, the STs of such isolates were 1839 (12 isolates), 2936 (two isolates), and 2935 (one isolate). Three cluster B isolates (6532, 6628, and 6451) had DNA that could be completely digested with *Sma*I; all three of these isolates had the same *fla* and *Sma*I PFGE profiles, and two were of ST-1839 (ST of the third isolate was not determined) (Fig. 1). The majority (12/14 [86%]) of the *Kpn*I-untypeable isolates were also in cluster B, and several (9/14) had DNA that was incompletely digested with *Sma*I (Fig. 1).

**Antimicrobial susceptibility profiles and strain subtypes.** Strains with some of the predominant antimicrobial resistance profiles tended to be found in the same cluster on the dendrogram constructed using *fla* typing and PFGE data. For instance, 15 of the 17 isolates with resistance profile 10 (ATSQ), and 9 of the 13 isolates with resistance profile 12 (ATSKQ), were placed in cluster B; isolates with less-predominant antimicrobial resistance profiles also tended to be in the same *fla*-PFGE cluster (Table 3). However, a bidirectional association between specific *fla*-PFGE fingerprints and antimicrobial resistance profiles was not observed except in the case of the two isolates with profile 13 (resistance to only tetracycline) and

the six isolates with profile 2 (AQ), which had related fingerprints ( $\geq 70\%$  similarity) (Fig. 1).

Similar findings were obtained with MLST. For instance, most (8/9) of the MLST-typed isolates with antimicrobial resistance profile 10 (ATSQ) had closely related STs: ST-1839 ( $n = 4$ ), ST-2935 ( $n = 1$ ), and ST-2936 ( $n = 3$ ). As mentioned earlier, ST-2935 and ST-2936 were closely related to ST-1839 (one allele difference each) (Fig. 2). All tested isolates with resistance profile 2 (AQ) had ST-2934, and all (of those tested) with profile 3 (AS) had ST-2132 (Table 3). However, bidirectional agreement between ST and resistance profile was detected only in the case of ST-1698, which was exclusively found in the two isolates with relatively rare resistance profile 13 (resistance to tetracycline only) (Table 3). These two isolates also harbored identical *fla*-PFGE fingerprints (Fig. 1). However, the availability of only two isolates with this resistance profile does not permit conclusions as to possible associations between ST-1698 and this resistance profile.

## DISCUSSION

In the current study, we analyzed population structure and resistance to several antimicrobials among 80 isolates of *C.*

FIG. 1. Dendrogram depicting *fla* and PFGE (*Sma*I and *Kpn*I) profiles of the 80 isolates investigated in this study. Cluster analysis of the patterns was performed by BioNumerics (version 4.6; Applied Maths). The arrow indicates a large undigested DNA band observed in isolates incompletely digested with *Sma*I. A, ampicillin; T, tetracycline; S, streptomycin; E, erythromycin; K, kanamycin; Q, (fluoro)quinolones (nalidixic acid and ciprofloxacin).




FIG. 3. *fla* and PFGE (SmaI and KpnI) diversity among isolates with the same ST. *fla*-PFGE subtypes of isolates with ST-1839 (A), ST-2132 (B), and ST-2934 (C). ARP refers to antimicrobial resistance patterns (Table 3).

*jejuni* from eastern North Carolina. None of the isolates were found to be resistant to chloramphenicol, gentamicin, or erythromycin. In contrast, we observed a high prevalence of resistance to ampicillin, tetracycline, streptomycin, kanamycin, nalidixic acid and ciprofloxacin, and most isolates were resistant to multiple (three or more) antimicrobials. Prevalence of resistance to ampicillin was noticeably higher in the current study than previously reported in conventionally grown turkeys (97.5% versus 12.5%) (24). Furthermore, none of the 80 isolates that we investigated were resistant to erythromycin, in contrast to the erythromycin resistance prevalence of 19.2% reported previously (24). MIC distributions in the current

study also showed several differences from those previously reported (24), especially in regard to ampicillin and tetracycline, for which MICs were noticeably higher among our isolates. Such differences could be caused by a variety of factors, including region, time period, and farm practices related to antimicrobial use.

Investigation of resistance profiles showed that most isolates resistant to kanamycin were also resistant to tetracycline, although the reverse was not the case. In *C. jejuni*, tetracycline resistance is typically conferred by plasmid-associated *tet*(O) (13, 35), and genetic determinants for resistance to kanamycin and tetracycline can be cotransferred via conjugation (19, 21).



Isolates that were resistant both to kanamycin and to tetracycline had diverse STs and *fla*-PFGE types, as did those in which resistance to tetracycline was not accompanied by kanamycin resistance. Such findings suggest that plasmids harboring a kanamycin resistance determinant as well as *tet*(O) may have disseminated among *C. jejuni* strains of different genetic backgrounds. It will be of interest to determine whether *C. coli* from turkeys may also exhibit the observed correlation between resistance to kanamycin and resistance to tetracycline.

The combination of *fla* typing and PFGE identified distinct subtypes among isolates of the same ST, which is consistent with findings reported by Bae et al. (5). These findings indicate the usefulness of MLST for detection of specific clonal groups, the population structure of which can then be characterized at higher resolution with *fla* typing and PFGE. Similar findings were described with multidrug-resistant clonal groups in *C. coli* isolates from turkeys (9).

In the case of *C. jejuni* isolates from turkeys, MLST may be especially valuable, because numerous isolates exhibited partial digestion with SmaI, and several also had DNA that could not be digested at all by KpnI, suggesting the presence of methylases. Interestingly, the putative methylases were largely a characteristic of one clonal group (*fla*-PFGE cluster B). The identification of a substantial number of isolates that were completely refractory to digestion with KpnI points to limitations concerning the use of this enzyme for PFGE of *C. jejuni* isolates from turkeys. The biological significance of DNA methylation such as that suggested by our data (partial methylation at SmaI sites and complete methylation at KpnI sites) remains to be investigated.

Of the 10 STs identified among the isolates that were subtyped by MLST in this study, three (ST-1839, ST-1162, and ST-1838) were previously reported only in turkey isolates. On the other hand, ST-1698 was encountered in an isolate from a chicken, and STs 1796 and 2132 were detected in isolates from human cases of illness (<http://www.pubmlst.org/campylobacter>). Further studies are needed to assess possible host associations of some of the STs (e.g., ST-1839 with turkeys).

We identified several isolates that were derived from different farms and had identical STs and either identical or closely related *fla*-PFGE patterns. Such findings suggest the dissemination of specific clonal groups among different farms in the turkey industry of the region. Possible vehicles for strain dissemination may include insects, other animals, groundwater, or human traffic (6, 15, 30, 31). Clonal groups were also identified among multidrug-resistant *C. coli* isolates from turkeys in this region (9, 22), as well as among *C. coli* and *C. jejuni* isolates from cattle and other meat animals (2, 5, 11, 20).

Several isolates with the same ST and identical or closely related PFGE patterns (with SmaI and KpnI) were found to have different *fla* types. Diversity in *fla* types among isolates with identical PFGE patterns was also described earlier in a study of *C. coli* isolates from successive turkey flocks at the same farm (22). The observed diversity in *fla* types among apparently related isolates likely reflects genetic instability involving the flagellin locus, described in several studies (16, 25, 38), and may contribute to antigenic diversity and host evasion strategies of the bacteria.

Isolates with certain antimicrobial resistance profiles were

found to have the same ST and belonged to the same *fla*-PFGE cluster. On the other hand, isolates with identical or closely related strain types often differed in antimicrobial resistance profiles. The latter types of isolates may have shared a common ancestor and acquired (or lost) determinants related to antimicrobial resistance, possibly in response to selection pressures related to exposure to relevant antimicrobial agents. Isolates with ST-2934 and antimicrobial resistance profiles 2 (AQ) and 8 (ATKQ) may represent an example of such a scenario. Such isolates had identical or closely related *fla*-PFGE patterns, and it is conceivable that the differences in their antimicrobial resistance profiles could reflect the presence or absence of a plasmid conferring resistance to both tetracycline and kanamycin and not detectable by PFGE subtyping. As discussed earlier, resistance to both kanamycin and tetracycline has been reported to be plasmid mediated in *Campylobacter* (19, 21).

In conclusion, the combined use of different subtyping schemes (*fla* typing, PFGE, MLST) has revealed distinct clonal groups of *C. jejuni* colonizing conventionally grown turkeys in eastern North Carolina, a major turkey production region in the United States. Although isolates of certain antimicrobial resistance profiles had identical or closely related strain types, strain subtype data generally did not allow the prediction of antimicrobial resistance profiles. Further studies are needed to determine whether genotypes and clonal groups of the isolates analyzed in this study are representative of those in other turkey-growing regions and to assess the extent to which *C. jejuni* strains and clonal groups predominant in turkeys may also be found in other animal hosts.

#### ACKNOWLEDGMENTS

The project was supported in part by the National Research Initiative of the USDA Cooperative State Research, Education and Extension Service, grant number 2003-0299.

This publication made use of the *Campylobacter jejuni* MLST website (<http://pubmlst.org/campylobacter/>) developed by Keith Jolley and Man-Suen Chan and sited at the University of Oxford. The development of this site has been funded by the Wellcome Trust.

#### REFERENCES

- Adak, G. K., J. M. Cowden, S. Nicholas, and H. S. Evans. 1995. The Public Health Laboratory Service national case-control study of primary indigenous sporadic cases of campylobacter infection. *Epidemiol. Infect.* **115**:15–22.
- Adhikari, B., J. H. Connolly, P. Madie, and P. R. Davies. 2004. Prevalence and clonal diversity of *Campylobacter jejuni* from dairy farms and urban sources. *N. Z. Vet. J.* **52**:378–383.
- Altekruse, S. F., and L. K. Tollefson. 2003. Human campylobacteriosis: a challenge to the veterinary profession. *J. Am. Vet. Med. Assoc.* **223**:445–451.
- Atanassova, V., F. Reich, L. Beckmann, and G. Klein. 2007. Prevalence of *Campylobacter* spp. in turkey meat from a slaughterhouse and in turkey meat retail products. *FEMS Immunol. Med. Microbiol.* **49**:141–145.
- Bae, W., D. D. Hancock, D. R. Call, Y. H. Park, A. C. Berge, R. M. Finger, W. M. Sischo, and T. E. Besser. 2007. Dissemination of antimicrobial resistant strains of *Campylobacter coli* and *Campylobacter jejuni* among cattle in Washington State and California. *Vet. Microbiol.* **122**:306–315.
- Bates, C., K. L. Hiatt, and N. J. Stern. 2004. Relationship of *Campylobacter* isolated from poultry and from darkling beetles in New Zealand. *Avian Dis.* **48**:138–147.
- Bull, S. A., V. M. Allen, G. Domingue, F. Jorgensen, J. A. Frost, R. Ure, R. Whyte, D. Tinker, J. E. Corry, J. Gillard-King, and T. J. Humphrey. 2006. Sources of *Campylobacter* spp. colonizing housed broiler flocks during rearing. *Appl. Environ. Microbiol.* **72**:645–652.
- Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
- D'lima, C. B., W. G. Miller, R. E. Mandrell, S. L. Wright, R. M. Siletzky, D. K. Carver, and S. Kathariou. 2007. Clonal population structure and



- specific genotypes of multidrug-resistant *Campylobacter coli* from turkeys. *App. Environ. Microbiol.* **73**:2156–2164.
10. Evans, S. J., and A. R. Sayers. 2000. A longitudinal study of campylobacter infection of broiler flocks in Great Britain. *Prev. Vet. Med.* **46**:209–223.
  11. Fitzgerald, C., K. Stanley, S. Andrew, and K. Jones. 2001. Use of pulsed-field gel electrophoresis and flagellin gene typing in identifying clonal groups of *Campylobacter jejuni* and *Campylobacter coli* in farm and clinical environments. *Appl. Environ. Microbiol.* **67**:1429–1436.
  12. Friedman, C. R., J. Neimann, H. C. Wegener, and R. V. Tauxe. 2000. Epidemiology of *Campylobacter jejuni* infections in the United States and other industrialized nations, p. 121–138. *In* I. Nachamkin and M. Blaser (ed.), *Campylobacter*, 2nd ed. American Society for Microbiology, Washington, DC.
  13. Gibreel, A., D. M. Tracz, L. Nonaka, T. M. Ngo, S. R. Connell, and D. E. Taylor. 2004. Incidence of antibiotic resistance in *Campylobacter jejuni* isolated in Alberta, Canada, from 1999 to 2002, with special reference to *ter(O)*-mediated tetracycline resistance. *Antimicrob. Agents Chemother.* **48**:3442–3450.
  14. Gillespie, I. A., S. J. O'Brien, J. A. Frost, G. K. Adak, P. Horby, A. V. Swan, M. J. Painter, and K. R. Neal. 2002. A case-case comparison of *Campylobacter coli* and *Campylobacter jejuni* infection: a tool for generating hypotheses. *Emerg. Infect. Dis.* **8**:937–942.
  15. Hänninen, M. L., M. Niskanen, and L. Korhonen. 1998. Water as a reservoir for *Campylobacter jejuni* infection in cows studied by serotyping and pulsed-field gel electrophoresis (PFGE). *Zentralbl. Veterinaermed. B* **45**:37–42.
  16. Harrington, C. S., F. M. Thomson-Carter, and P. E. Carter. 1997. Evidence for recombination in the flagellin locus of *Campylobacter jejuni*: implications for the flagellin gene typing scheme. *J. Clin. Microbiol.* **35**:2386–2392.
  17. Heuer, O. E., K. Pedersen, J. S. Andersen, and M. Madsen. 2001. Prevalence and antimicrobial susceptibility of thermophilic *Campylobacter* in organic and conventional broiler flocks. *Lett. Appl. Microbiol.* **33**:269–274.
  18. Hunter, P. R., and M. A. Gaston. 1988. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. *J. Clin. Microbiol.* **26**:2465–2466.
  19. Kotarski, S. F., T. L. Merriwether, G. T. Tkalecic, and P. Gemski. 1986. Genetic studies of kanamycin resistance in *Campylobacter jejuni*. *Antimicrob. Agents Chemother.* **30**:225–230.
  20. Kwan, P. S., A. Birtles, F. J. Bolton, N. P. French, S. E. Robinson, L. S. Newbold, M. Upton, and A. J. Fox. 2008. Longitudinal study of the molecular epidemiology of *Campylobacter jejuni* in cattle on dairy farms. *Appl. Environ. Microbiol.* **74**:3626–3633.
  21. Lambert, T., G. Gerbaud, P. Trieu-Cuot, and P. Courvalin. 1985. Structural relationship between the genes encoding 3'-aminoglycoside phosphotransferase in *Campylobacter* and in gram-positive cocci. *Ann. Inst. Pasteur Microbiol.* **136**:135–150.
  22. Lee, B. C., N. Reimers, H. J. Barnes, C. D'lima, D. Carver, and S. Kathariou. 2005. Strain persistence and fluctuation of multiple-antibiotic resistant *Campylobacter coli* colonizing turkeys over successive production cycles. *Foodborne Pathog. Dis.* **2**:103–110.
  23. Logue, C. M., J. S. Sherwood, L. M. Elijah, P. A. Olah, and M. R. Dockter. 2003. The incidence of *Campylobacter* spp. on processed turkey from processing plants in the midwestern United States. *J. Appl. Microbiol.* **95**:234–241.
  24. Luangtongkum, T., T. Y. Morishita, A. J. Ison, S. Huang, P. E. McDermott, and Q. Zhang. 2006. Effect of conventional and organic production practices on the prevalence and antimicrobial resistance of *Campylobacter* spp. in poultry. *Appl. Environ. Microbiol.* **72**:3600–3607.
  25. Meinersmann, R. J., R. W. Phillips, K. L. Hiatt, and P. Fedorka-Cray. 2005. Differentiation of *Campylobacter* populations as demonstrated by flagellin short variable region sequences. *Appl. Environ. Microbiol.* **71**:6368–6374.
  26. Miller, W. G., M. D. Englen, S. Kathariou, I. V. Wesley, G. Wang, L. Pittenger-Alley, R. M. Siletzky, W. Muraoka, P. J. Fedorka-Cray, and R. E. Mandrell. 2006. Identification of host-associated alleles by multilocus sequence typing of *Campylobacter coli* strains from food animals. *Microbiology* **152**:245–255.
  27. Miller, W. G., S. L. W. On, G. Wang, S. Fontanoz, A. J. Lastovica, and R. E. Mandrell. 2005a. Extended multilocus sequence typing system for *Campylobacter coli*, *C. lari*, *C. upsaliensis*, and *C. helveticus*. *J. Clin. Microbiol.* **43**:2315–2329.
  28. Nachamkin, I., B. M. Allos, and T. Ho. 1998. *Campylobacter* species and Guillain-Barré syndrome. *Clin. Microbiol. Rev.* **11**:555–567.
  29. Nachamkin, I., J. Engberg, and F. M. Aarestrup. 2000. Diagnosis and antimicrobial susceptibility of *Campylobacter* species, p. 45–66. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. American Society for Microbiology, Washington, DC.
  30. Newell, D. G., and C. Fearnley. 2003. Sources of *Campylobacter* colonization in broiler chickens. *Appl. Environ. Microbiol.* **69**:4343–4351.
  31. Pacha, R. E., G. W. Clark, E. A. Williams, A. W. Carter, J. J. Scheffelmaier, and P. Debusschere. 1987. Small rodents and other mammals associated with mountain meadows as reservoirs of *Giardia* spp. and *Campylobacter* spp. *Appl. Environ. Microbiol.* **53**:1574–1579.
  32. Skirrow, M. B., and M. J. Blaser. 2000. Clinical aspects of *Campylobacter* infection, p. 69–88. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. American Society for Microbiology, Washington, DC.
  33. Smith, K., N. Reimers, H. J. Barnes, B. C. Lee, R. Siletzky, and S. Kathariou. 2004. *Campylobacter* colonization of sibling turkey flocks reared under different management conditions. *J. Food Prot.* **67**:1463–1468.
  34. Stern, N. J., and S. Pretanik. 2006. Counts of *Campylobacter* spp. on U. S. broiler carcasses. *J. Food Prot.* **69**:1034–1039.
  35. Taylor, D. E., and P. Courvalin. 1988. Mechanisms of antibiotic resistance in *Campylobacter* species. *Antimicrob. Agents Chemother.* **32**:1107–1112.
  36. Van Looveren, M., G. Daube, L. De Zutter, J.-M. Dumnon, C. Lammens, M. Wijdooghe, P. Vandamme, M. Jouret, M. Cornelis, and H. Goossens. 2001. Antimicrobial susceptibilities of *Campylobacter* strains isolated from food animals in Belgium. *J. Antimicrob. Chemother.* **48**:235–240.
  37. Wallace, J. S., K. N. Stanley, and K. Jones. 1998. The colonization of turkeys by thermophilic campylobacters. *J. Appl. Microbiol.* **85**:224–230.
  38. Wassenaar, T. M., B. N. Fry, and B. A. van der Zeijst. 1995. Variation of the flagellin gene locus of *Campylobacter jejuni* by recombination and horizontal gene transfer. *Microbiology* **141**:95–101.
  39. Wesley, I. V., W. T. Muraoka, D. W. Trampel, and H. S. Hurd. 2005. Effect of preslaughter events on prevalence of *Campylobacter jejuni* and *Campylobacter coli* in market-weight turkeys. *Appl. Environ. Microbiol.* **71**:2824–2831.
  40. Wright, S. L., D. K. Carver, R. M. Siletzky, S. Romine, W. E. M. Morrow, and S. Kathariou. 2008. Longitudinal study of prevalence of *Campylobacter jejuni* and *Campylobacter coli* from turkeys and swine grown in close proximity. *J. Food Prot.* **71**:1791–1796.